Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 5/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25148400 | 1.00 | SMO (0.40) | SMOP2RX3P2RX2KDM4ECCR2 | |
| SCHEMBL25147750 | 0.89 | SMO (0.34) | SMOKDR | |
| SCHEMBL31659593 | 0.89 | SMO (0.34) | SMOKDR | |
| SCHEMBL30332147 | 0.85 | GRIN2D (0.32) | P2RX3P2RX2 | |
| SCHEMBL25147780 | 0.85 | GRIN2D (0.32) | P2RX3P2RX2 | |
| SCHEMBL25147713 | 0.84 | GRIN2D (0.31) | — | |
| SCHEMBL30331753 | 0.84 | GRIN2D (0.31) | — | |
| SCHEMBL31659632 | 0.83 | P2RX3 (0.32) | P2RX3P2RX2 | |
| SCHEMBL25148371 | 0.83 | P2RX3 (0.32) | P2RX3P2RX2 | |
| SCHEMBL25153188 | 0.83 | KDM4E (0.35) | SMOP2RX3P2RX2KDM4ECCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM5, CHRM4, CHRM1 | SMO 1526/4885P2RX3 439/4885P2RX2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.